References
- Aebi S, Kurdi-Haidar B, Gordon R, et al (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res, 56, 3087-90.
- Andrea U, Julia P and Sergio B (2005). A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics, 5, 796-804. https://doi.org/10.1002/pmic.200401147
- Canman CE, Radany EH, Parsels LA, et al (1994). Davis MA, Lawrence TS and Maybaum J: Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichi a coli deoxyuridinetriphosphatase. Cancer Res, 54, 2296-8.
- Cecconi D, Donadelli M, Scarpa A, et al (2005). Proteomic analysis pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. J Proteome Res, 4, 1909-16. https://doi.org/10.1021/pr050154j
- Chua BT, Volbracht C, Tan KO, et al (2003). Mitochondrial translocation of cofilin is an early step in apoptosis induction. Nat Cell Biol, 5, 1083-9. https://doi.org/10.1038/ncb1070
- DesMarais V, Ghosh M, Eddy R, et al (2005). Cofilin takes the lead. J Cell Sci, 118, 19-26. https://doi.org/10.1242/jcs.01631
- Hamada S, Kamada M, Furumoto H, et al (1994). Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol, 52, 313-9. https://doi.org/10.1006/gyno.1994.1055
- Jemal A, Siegel R, Ward E et al (2009). Cancer statistics. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
- Kartalou M and Essigmann JM (2001). Mechanisms of resistance to cisplatin. Mutat Res, 478, 23-43. https://doi.org/10.1016/S0027-5107(01)00141-5
- Kim SW, Kim S, Nam EJ, et al (2011). Comparative Proteomic Analysis of Advanced Serous Epithelial Ovarian Carcinoma: Possible Predictors of Chemoresistant disease. OMICS, 15, 281-92. https://doi.org/10.1089/omi.2010.0012
- Liu CC, Lu TC, Li HH, et al (2010). Phosphoproteomic identifi-cation and phylogenetic analysis of ribosomal P-proteins in Populus dormant terminal buds. Planta, 231, 571-81. https://doi.org/10.1007/s00425-009-1037-9
- Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. https://doi.org/10.1006/meth.2001.1262
- Marth C, Widschwendter M, KaernJ, et al (1997). Cisplatin resistance is associated with reduced interfer on-gammasensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Cance, 76, 1328-32. https://doi.org/10.1038/bjc.1997.556
- Ozols RF and Young RC (1985). High-dose cisplatin therapy in ovarian cancer. Semin Oncol, 12, 21-30.
- Rudin CM, Yang Z, Schumaker LM, et al (2003). Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res, 63, 312-8.
- Sasaki H, Sheng Y, Kotsuji F and Tsang BK (2000). Downregulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res, 60, 5659-66.
- Veneroni S, Zaffaroni N, Daidone MG, et al (1994). Expression of P-glycoprote-in and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer, 30A, 1002-7. https://doi.org/10.1016/0959-8049(94)90132-5
- Wang WG, Goswami S, Lapidus K, et al (2004). Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res, 64: 8585-94. https://doi.org/10.1158/0008-5472.CAN-04-1136
- Wang W, Mouneimne G, Sidani M, et al (2006). The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol, 173, 395-404. https://doi.org/10.1083/jcb.200510115
- Williams J, Lucas PC, Griffith KA, et al (2005). Expression of BclxL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol, 96, 287-95. https://doi.org/10.1016/j.ygyno.2004.10.026
- Wong CS, Wong VW, Chan CM, et al (2008). Identification of 5-fluorouracil response proteins in colorectal cacinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Pep, 20, 89-98.
- Yuan ZQ, Feldman RI, Sussman GE, et al (2003). AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1-Implication of AKT2 in chemoresistance. J Biol Chem, 278, 23432-40 https://doi.org/10.1074/jbc.M302674200
- Yuan Z, Wang F , Zhao ZW, et al (2011). BIM-Mediated AKT Phosphory-lation Is a Key Modulator of Arsenic Trioxide-Induced Apoptosis in Cisplatin-Sensitive and-Resistant Ovarian Cancer Cells. PLOS ONE, 6, e20586. https://doi.org/10.1371/journal.pone.0020586
- Yang JW, Rodrigo R, Felipo V and Lubec GJ (2005), Proteome analysis of primary neurons and astrocytes from rat cerebellum. J Proteome Res, 4, 768-88. https://doi.org/10.1021/pr049774v
- Yan XD, Pan LY, Yuan Y, et al (2007). Identification of platinumresistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res, 6, 772-80. https://doi.org/10.1021/pr060402r
- Zhou YZ, Chen HZ and Yang QY (1996). Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance. Natl Med J China, 76, 680-3.
- Zhu BB, Fukada K, Zhu HN and Kyprianou N (2006). Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Res, 66, 8640-7. https://doi.org/10.1158/0008-5472.CAN-06-1443
Cited by
- Adriamycin resistance-associated prohibitin gene inhibits proliferation of human osteosarcoma MG63 cells by interacting with oncogenes and tumor suppressor genes vol.12, pp.3, 2016, https://doi.org/10.3892/ol.2016.4862